Connect with us

Hi, what are you looking for?

Saturday, Dec 3, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

International

Short Wave and Sheba partner for clinical trial aimed at combatting anorexia

Innovative new studies in the Middle East receive approval from Israeli Ministry of Health

Short Wave and Sheba partner for clinical trials aimed at combatting anorexia
Photo via Sheba Medical Centre

Psilocybin has been gaining a great deal of interest in recent days for a variety of reasons, and as more scholars and researchers from different disciplines around the world have started to recognize its potential the number of clinical uses for it is also increasing.

On Monday, Shortwave Pharma Inc. announced that it had signed a clinical trial agreement with the Sheba Fund for Health Services and Research and the two head Investigators’ at the Sheba Medical Centre Department for Eating Disorders.

The new agreement will appoint Shortwave as the exclusive commercial partner in an “investigator-initiated, open-label, phase II study of the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa.”

Photo via Shortwave Pharma

Read more: Lobe Sciences partners with iNGENū for new clinical trials in Australia

Read more: Serenus Global becomes Health Canada licensed psilocybin distributor

Shortwave Pharma is an Israeli pre-clinical stage biotech company focused on the development of novel formulations of psilocybin, other active pharmaceutical ingredients (APIs) and custom-designed delivery methods for those drugs. Treating mental and physical health disorders is the company’s primary objective.

The Centre for Eating Disorders at the Sheba Medical Centre is the largest facility of its kind in Israel. The centre provides treatment for adult patients suffering from a variety of eating disorders including anorexia nervosa, binge eating disorder and bulimia nervosa. The facility employs physicians, social workers, dietitians and psychologists.

Shortwave says that the new trial will be the first of its kind in Israel. It also says that the organizations’ have received approval from the Israeli Ministry of Health for the new research endeavour and are currently preparing to recruit participants.

The patent-pending psilocybin-based formulation created by Shortwave is intended to target several receptors that contribute to the prevalence of anorexia via a proprietary oral (or buccal) method of administration.

Both Shortwave and the Sheba Fund have agreed to cooperate going forward post-trial and to consider an ensuing study utilizing Shortwave’s psilocybin-based formulation and oral delivery method.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

 

 

 

 

 

 

 

 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Business

The company's rubber will have a 'double pocket' containing a special lubricant for enhanced intercourse

International

The company has sent thousands of extract vials with various cannabinoid concentrations to Germany

Canada

The cohort led by TheraPsil will be meeting with parliament members and protesting outside the Centre Block

Psychedelics

The bill would reduce 'unreasonably burdensome rules and regulations'